Time Restricted Feeding and Metabolic Rhythms (Rhythm)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Time restricted feeding (TRF; eating within <10-h period followed by >14-h fast) is a promising meal timing paradigm that in rodent studies improves multiple health indicators. When provided access to a high-fat diet ad libitum, mice rapidly gain weight. However, when fed the same diet under TRF conditions (food access restricted to an 8-h window during the active phase) mice appear to be protected from excessive weight gain and metabolic diseases. Preliminary studies in humans are showing improvements in 24-h glucose variability, fat oxidation, and blood pressure with TRF aligned to the early portion of the day compared to the ad libitum feeding schedule. A major research gap is whether the timing of the feeding window relative to sleep modifies metabolic responses. In a recent pilot and feasibility study incorporating TRF into a weight loss intervention the researchers asked participants to consume all food within a 10-h window to starting 1-h after waking for 12-weeks. The researchers' design choice was based on data showing that consuming energy in the evening is related to a two-fold increase in obesity risk. There also appears to be reduced weight loss effectiveness in dieters who consume the main meal later in the day. Some of the participants in the weight loss trial reported difficulty adhering to the early feeding schedule because it does not align well with social schedule (e.g., eating dinner with the family in the evening). Therefore, an important clinical question is whether late or mid-day TRF will result in similar metabolic benefits compared to the early TRF paradigm that has been tested in other studies.
Additional rationale for studying early vs. late timed feeding is to address a fundamental question, "can timed meals shift the timing of metabolic rhythms?". Peripheral circadian clocks located in liver, adipose, and muscle tissue are sensitive to meal timing and control daily oscillations in fuel utilization and storage. A small study of 8 men demonstrated that a 5-h delay and meal timing was sufficient to delay the rhythmic expression of clock genes in white adipose tissue. Therefore, the investigators will leverage the design of the present study to examine the impact of meal timing on peripheral circadian rhythms in metabolism and their alignment to the sleep cycle.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Anschutz Medical Campus
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women with overweight and class I obesity (N=12, Age=20-50 years; BMI 25-35 kg/m2)
- Low physical activity level (≤150 min/wk of moderate-to-vigorous activity);
- For Females- Not currently pregnant or lactating and not pregnant within the past 6 months
- Habitually consume food over a window of >12 h/day;
- Pass a medical and physical screening performed by the study physician.
- Report a habitual, regular sleep-wake cycle for the month preceding screening that involved going to bed between 2200 and 0100h and getting up between 0600 and 0900 h with >7 h and <9.25 h in bed;
- Agree to eat control diets at imposed times for 1 week prior to the inpatient CTRC visits;
- Agree to keep a regular sleep/wake schedule for the duration of the study
- Possess a smart phone to install and utilize the meal timing application.
Exclusion Criteria:
- Subjects must not be currently participating in another research study that would influence their safe participation in this study. For example, subjects must not be participating in a research study in which they ingest experimental medication, or which involves blood samples, since both of these factors could increase risk of participation;
- Being considered unsafe to participate as determined by the study physician;
- Taking medications affecting weight, triglycerides, energy intake/energy expenditure, or sleep in the last 3 months;
Having abnormal blood chemistry and/or hematology as deemed significant by the study physician;
o Have one or more of the following out-of-range values measured on a fasting blood sample: glucose > 126 mg/dl, HbA1c > 6.5%, thyroid stimulating hormone <0.5 or >5.0 uU/ml. Subjects who may be anemic (hemoglobin <14.5 g/dl men, <12.3 g/dl women), have abnormal liver function tests (alanine amino transferase > 47 U/l, aspartate aminotransferase, > 47 U/l, alkaline phosphatase <39 or >117 U/l) or creatinine (>1.1 mg/dl)
- Significant abnormality in clinical laboratory values
- Ever having a history of systemic, psychiatric, neurological disease, or drug and alcohol abuse;
- History of cardiovascular disease, diabetes, uncontrolled hypertension, untreated thyroid, renal, hepatic diseases, dyslipidemia or any other medical condition affecting weight or lipid metabolism;
- Score > 18 on Beck Depression Index (BDI) will require further assessment by the study physician to determine if it is appropriate for the subject to participate in the study;
- Use of a continuous positive airway pressure (CPAP) device for the treatment of obstructive sleep apnea (OSA). A score of >10 on the Epworth sleepiness scale or >5 on the Pittsburgh Sleep Quality Index will require further assessment by the study physician to determine if it is appropriate for the subject to participate in the study;
- Being positive for human immunodeficiency virus or hepatitis B or C;
- Being a smoker or having been a smoker in the previous 6 months;
- Abnormal eating patterns identified by registered dietician interview (dietary fat<15%, dietary fat>45%, dietary protein >30%);
- Working night shifts;
- Night eating syndrome (at least 25% of food intake is consumed after the evening meal and/or at least two episodes of nocturnal eating per week);
- Traveling > 2 time zones 2 weeks prior to an inpatient CTRC study visit;
- Currently participating in any formal weight loss or physical activity programs or clinical trials.
- Having a clinically significant allergy (e.g., to food stuffs such as shellfish, peanuts);
- Celiac disease or known sensitivity to gluten (the metabolic kitchen is not gluten free certified and cannot accommodate this dietary restriction)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Early Time Restricted Feeding
Consume meals for 7 days during an 8 hour window starting 1 hour after habitual wake time.
|
Consuming energy during a short interval during the day
|
|
Experimental: Mid-day Time Restricted Feeding
Consume meals for 7 days during an 8 hour window starting 6 hours after habitual wake time.
|
Consuming energy during a short interval during the day
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total fat oxidation in response to eTRF
Time Frame: Week 1 or Week 5
|
Total fat oxidation will measured by whole room calorimetry.
Early Time Restricted Feeding (eTRF) may occur at Week 1 or Week 5 depending on randomization.
|
Week 1 or Week 5
|
|
Total fat oxidation in response to mTRF
Time Frame: Week 1 or Week 5
|
Total fat oxidation will measured by whole room calorimetry.
Mid-day Time Restricted Feeding (mTRF) may occur at Week 1 or Week 5 depending on randomization.
|
Week 1 or Week 5
|
|
Insulin sensitivity in response to eTRF
Time Frame: Week 1 or Week 5
|
Insulin sensitivity measured by three identical mixed meal tolerance tests administered across the day.
Early Time Restricted Feeding (eTRF) may occur at Week 1 or Week 5 depending on randomization.
|
Week 1 or Week 5
|
|
Insulin sensitivity in response to mTRF
Time Frame: Week 1 or Week 5
|
Insulin sensitivity measured by three identical mixed meal tolerance tests administered across the day.
Mid-day Time Restricted Feeding (mTRF) may occur at Week 1 or Week 5 depending on randomization.
|
Week 1 or Week 5
|
|
Glucose control in response to eTRF
Time Frame: Week 1 or Week 5
|
Glucose control will be measured by a continuous glucose monitor.
Mid-day Time Restricted Feeding (mTRF) may occur at Week 1 or Week 5 depending on randomization.
|
Week 1 or Week 5
|
|
Glucose control in response to mTRF
Time Frame: Week 1 or Week 5
|
Glucose control will be measured by a continuous glucose monitor.
Early Time Restricted Feeding (eTRF) may occur at Week 1 or Week 5 depending on randomization.
|
Week 1 or Week 5
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in dietary fat oxidation between experimental conditions
Time Frame: Week 1 and Week 5
|
Dietary fat oxidation will be measured using a stable isotope tracer
|
Week 1 and Week 5
|
|
Difference in 24h energy expenditure between experimental conditions
Time Frame: Week 1 and Week 5
|
24h energy expenditure will be measured using whole room calorimetry
|
Week 1 and Week 5
|
|
Difference in sleep between experimental conditions
Time Frame: Week 1 and Week 5
|
Sleep will be measured by polysomnography
|
Week 1 and Week 5
|
|
Difference in the melatonin rhythm between experimental conditions
Time Frame: Week 1 and Week 5
|
The melatonin profile will be measured in plasma during constant routine protocol
|
Week 1 and Week 5
|
|
Difference in plasma metabolite rhythms between experimental conditions
Time Frame: Week 1 and Week 5
|
Plasma metabolite rhythms will be measured using a constant routine protocol
|
Week 1 and Week 5
|
|
Difference in plasma hormone rhythms between experimental conditions
Time Frame: Week 1 and Week 5
|
Plasma hormone rhythms will be measured using a constant routine protocol
|
Week 1 and Week 5
|
|
Difference in plasma gene expression rhythms between experimental conditions
Time Frame: Week 1 and Week 5
|
Plasma gene expression rhythms will be measured using a constant routine protocol
|
Week 1 and Week 5
|
|
Difference in energy expenditure rhythms between experimental conditions
Time Frame: Week 1 and Week 5
|
Energy expenditure rhythms will be measured by indirect calorimetry during a constant routine protocol
|
Week 1 and Week 5
|
|
Difference in substrate oxidation rhythms between experimental conditions
Time Frame: Week 1 and Week 5
|
Substrate oxidation rhythms will be measured by indirect calorimetry during a constant routine protocol
|
Week 1 and Week 5
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Corey A Rynders, PhD, University of Colorado - Anschutz Medical Campus
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 16-2754
- K01DK113063 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
NCT06671119RecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical Conditions
-
NCT05938335Not yet recruiting
-
NCT02645422Enrolling by invitation
-
NCT04780828CompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, Visceral
-
NCT03203161Not yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric Surgery
-
NCT06734312RecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation Techniques
-
NCT03843424CompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood
-
NCT04698135CompletedMorbid Obesity | Metabolically Healthy Obesity
-
NCT03219658Completed
-
NCT03899311Completed
Clinical Trials on Time Restricted Feeding
-
NCT05964179CompletedNutritional and Metabolic Diseases | Body Weight Maintenance
-
NCT06858683RecruitingObesity and Obesity-related Medical Conditions
-
NCT06899997RecruitingObesity and Obesity-related Medical Conditions
-
NCT03439618Unknown
-
NCT07505680CompletedCircadian Rhythm | Appetite | Metabolic Health | Body Weight Control | Glycemic and Insulinemic Response
-
NCT04389970CompletedMultiple Sclerosis | Diet, Healthy
-
NCT03823872CompletedWeight Loss | Overweight and Obesity
-
NCT05598515Completed
-
NCT04580433CompletedObesity | Polycystic Ovary Syndrome | Overweight
-
NCT04000516CompletedTime Restricted Feeding